Roche Diagnostics CEO Matt Sause echoed Schinecker's comments, noting that the decline in the diagnostics business was entirely driven by the decrease in COVID-19 testing sales. Between 80 percent and 90 percent of the COVID-19-related sales will be "washed out" by Q4 2023, he said. The "entire impact" of the COVID-19 decline was within the diagnostics business, and the company expects the COVID-19 impact to get smaller over the course of 2023 and the overall impact to disappear completely by the end of Q1 2024, he added. Schinecker noted on the call that the COVID-19 sales decline was in line with the guidance Roche provided at the beginning of 2023. Schinecker said in a statement that "sales in the base business of both our divisions grew strongly, largely offsetting the impact of declining demand for COVID-19 products."ĬOVID-19 test sales in the period were CHF 400 million, down from CHF 3.1 billion in the first half of 2022. The diagnostics base business saw growth of CHF 421 million, Roche CEO Thomas Schinecker said on a conference call to discuss the firms results. Revenues for the Diagnostics division cam e in at CHF 7.10 billion, down 29 percent (and 23 percent at constant exchange rates) compared to CHF 9.95 billion in revenues during the same period last year. The firm's base business excluding COVID-19 product sales grew 8 percent at constant exchange rates. At constant exchange rates the decline was 2 percent. The company also emphasized the importance of recent and upcoming diagnostics product launches that will broaden its portfolio and continue to boost its base business.įor the first half of 2023, the Roche Group reported CHF 29.78 billion ($34.75 billion) in total sales, down 8 percent from CHF 32.30 billion during the first half of 2022. However, excluding those products, its base Dx business saw 6 percent growth at constant exchange rates, driven by growth in immunodiagnostics and clinical chemistry. NEW YORK – Roche on Thu rsday reported its Diagnostics division revenues fell 29 percent year over year in the first half of 2023 as a result of expected lower demand for COVID-19 tests. Note: This story has been updated with comments from the company's conference call to discuss its financial results. Advances in Clinical Genomics Profiling.For more information, please contact your insurance provider. It is your responsibility to know whether your insurance covers lab work provided by one of our partners. We partner with Central Coast Pathology and Pacific Diagnostic Laboratories (PDL) for laboratory and pathology services. Sansum Clinic patients can have their lab work done at any PDL patient service center location. Monday-Thursday 8:00 AM to 12 Noon and 1:00 PM to 5:00 PM Friday 8:00 AM to 12 noon Monday-Thursday 7:00 AM to 5:00 PM, Friday 7:00 AM to 12 noon Pesetas Urgent Care & Multi-Specialty Clinic Mon-Thurs 7 AM to 5 PM Fri 7 AM to 12 Noon In Santa Barbara, laboratory services are provided onsite by Pacific Diagnostic Laboratories.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |